US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Sionna Therapeutics / Equity Capital Markets

<ul>
<li>The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".</li>
<li>This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).</li>
<li>Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. </li>
</ul>


The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".
This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).
Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. 


Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.</li>
<li>The terms value the company between $652m-$734m with the $16-$18 price range.</li>
<li>The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.</li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.
The terms value the company between $652m-$734m with the $16-$18 price range.
The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.


Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

Maze Therapeutics / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/maze-therapeutics-inc" target="_blank" data-smartkarma-citation="entities:44247:1" rel="noopener">Maze Therapeutics (MAZE US)</a> upsized its transaction but saw its IPO price dip below issue on day one.</li>
<li>A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.</li>
<li>With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.</li>
</ul>



Maze Therapeutics (MAZE US) upsized its transaction but saw its IPO price dip below issue on day one.
A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.
With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.


Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

<ul>
<li>The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. </li>
<li>According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.</li>
<li>Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.</li>
</ul>


The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. 
According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.
Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.


Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

<ul>
<li>The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.</li>
<li>The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.</li>
<li>The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.</li>
</ul>


The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.
The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.
The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.


Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

United States

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic diseases, including obesity.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Maze Therapeutics (MAZE US)

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

​Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

​Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

​Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

​Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

​Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...